Understanding youth and young adult cannabis use in Canada post-legalization: a scoping review on a public health issue.

Understanding youth and young adult cannabis use in Canada post-legalization: a scoping review on a public health issue.

Publication date: Jun 17, 2024

Canada legalized recreational cannabis in 2018, and one of the primary objectives of the Cannabis Act was to protect youth by reducing their access to cannabis and providing public education. Canada has the highest prevalence of cannabis use worldwide, particularly among youth and young adults under the age of 25. Cannabis use is linked with many adverse effects for youth and young adults including psychosis, anxiety, depression, respiratory distress, cannabinoid hyperemesis syndrome, and impaired cognitive performance. Despite the high prevalence of cannabis use and the evolution of policies in Canada and globally, significant knowledge and research gaps remain regarding youth and young adult cannabis use. The aim of this scoping review is to map the extent, nature, and range of evidence available on youth and young adult cannabis use in Canada since its legalization, in order to strengthen policies, services, treatments, training, and public education strategies. Using a scoping review framework developed by Arksey and O’Malley, along with the PRISMA-ScR guidelines, we conducted a rigorous search in five academic databases: MEDLINE, Embase, APA PsycINFO, CINAHL and Web of Science Core Collection. We included empirical studies that collected data in Canada after the legalization of recreational cannabis (October 2018) and focused on youth or young adults 

Open Access PDF

Concepts Keywords
Canada Adolescent
Cannabis Adult
October Canada
Training Canada
Worldwide Cannabis
COVID-19
Humans
Legalization
Legislation, Drug
Marijuana Use
Public Health
Public health
Regulation
Scoping review
Young Adult
Young adults
Youth

Semantics

Type Source Name
drug DRUGBANK Medical Cannabis
disease VO Canada
disease MESH psychosis
disease MESH syndrome
disease VO Apa
pathway REACTOME Reproduction
disease MESH Substance Abuse
disease MESH emergency
disease MESH psychosocial functioning
disease MESH lung injury
disease MESH myocardial ischemia
disease MESH seizures
disease MESH weight loss
drug DRUGBANK Ethanol
disease MESH cannabis dependence
drug DRUGBANK Dronabinol
disease IDO intervention
disease VO protocol
disease VO document
drug DRUGBANK Methionine
disease IDO process
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH COVID 19 pandemic
disease VO population
drug DRUGBANK Nicotine
disease IDO quality
disease MESH bullying
disease VO edible
disease MESH tachycardia
disease VO frequency
drug DRUGBANK Iron
disease MESH suicide
disease MESH suicidal ideation
drug DRUGBANK Fenamole
disease MESH loneliness
disease VO Gap
disease VO age
drug DRUGBANK Adenosine
disease MESH bipolar disorder
disease IDO history
disease VO time
disease MESH adverse childhood experiences
drug DRUGBANK Icodextrin
disease VO vein
drug DRUGBANK Trestolone
disease VO effective
drug DRUGBANK Ranitidine
drug DRUGBANK Diethylstilbestrol
disease VO report
disease MESH Alcohol Abuse
disease MESH sequelae
drug DRUGBANK Roxithromycin
disease MESH schizophrenia
disease MESH Dual Diagnosis
disease VO USA
drug DRUGBANK Minaprine
disease VO volume
disease MESH Marijuana Use

Original Article

(Visited 2 times, 1 visits today)